Role of Novel RADA16 Hydrogel in Endoscopic Skull Base Surgery
Skull Base Neoplasms, Cerebrospinal Fluid Leakage, Nasal; Hypertrophy, Mucous Membrane (Septum)
About this trial
This is an interventional treatment trial for Skull Base Neoplasms focused on measuring Nasoseptal Flap Harvest, Sinonasal Morbidity, Extracellular Matrix, Endoscopic Skull Base Surgery
Eligibility Criteria
Inclusion Criteria: Patient is 18 years of age or older Patient is undergoing endoscopic endonasal approach for the management of a skull base tumor or cerebrospinal fluid leak. Nasoseptal Flap must be harvested. Patient is undergoing surgery via bi-nostril approach requiring bilateral surgical dissection of the nasal cavity in approach to the skull base Exclusion Criteria: Patient has evidence of radiographic baseline sinus disease consistent with acute or chronic rhinosinusitis (including nasal polyposis, prior septal perforation) on pre-operative CT sinus Patient has had prior sinonasal surgery or has undergone sinonasal radiation treatment Patient has a known coagulation disorder or immune deficiency.
Sites / Locations
- Indiana University
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
PuraGel (RADA16) Hydrogel
Non-absorbable Packing (Silastic Splint)
Participant will have PuraGel (RADA16) Hydrogel applied to the nasoseptal flap harvest site following endoscopic skull base surgery
Participant will have a silastic splint (Non-Absorbable Packing) applied to the nasoseptal flap harvest site following endoscopic skull base surgery with no additional packing or agent